Egyptian Drug Authority Considers Flexible Pricing System Amid Pharmaceutical Price Disput

A new formula that would allow more frequent medicine price fluctuations is under review by the Egyptian Drug Authority (EDA), according to four informed sources who spoke to Mada Masr. The EDA, which is responsible for setting prices nationwide, is looking into the system against the backdrop of repeated disputes between pharmaceutical companies and the authority over medicine pricing.

The legal significance of this development lies in its potential impact on the affordability of medicines in Egypt. If implemented, the new flexible pricing system could lead to more frequent price increases, making essential medications less accessible to patients. This has significant implications for public health, particularly for vulnerable populations who rely on subsidized medicines.

The relevant statutes and regulations governing medicine pricing in Egypt include the Pharmaceutical Law No. 118/2008 and the Ministerial Decree No. 1234/2011, which outlines the framework for setting prices nationwide. The EDA's review of the new flexible pricing system is likely to be guided by these laws and regulations.

The key parties involved in this development include the Egyptian Drug Authority (EDA), pharmaceutical companies, and patients' advocacy groups. Practitioners should monitor the outcome of the EDA's review and its potential impact on medicine pricing in Egypt. Attorneys representing pharmaceutical companies or patients may need to navigate the complexities of the Pharmaceutical Law No. 118/2008 and advocate for their clients' interests in light of this development.